Evelyn Partners Investment Management Services Ltd Sells 9,867 Shares of The Cooper Companies, Inc. $COO

Evelyn Partners Investment Management Services Ltd trimmed its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 94.4% in the second quarter, HoldingsChannel reports. The firm owned 585 shares of the medical device company’s stock after selling 9,867 shares during the period. Evelyn Partners Investment Management Services Ltd’s holdings in Cooper Companies were worth $42,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in COO. Zions Bancorporation National Association UT acquired a new position in shares of Cooper Companies during the first quarter worth approximately $33,000. GKV Capital Management Co. Inc. purchased a new position in Cooper Companies during the first quarter worth about $40,000. J.Safra Asset Management Corp boosted its stake in shares of Cooper Companies by 204.8% in the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after buying an additional 340 shares during the last quarter. Assetmark Inc. grew its stake in Cooper Companies by 357.8% in the 2nd quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 483 shares during the period. Finally, Allworth Financial LP raised its stake in shares of Cooper Companies by 36.6% during the 2nd quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock worth $68,000 after purchasing an additional 257 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Insider Buying and Selling at Cooper Companies

In related news, COO Gerard H. Warner III bought 1,450 shares of the business’s stock in a transaction on Friday, September 5th. The stock was acquired at an average price of $69.23 per share, for a total transaction of $100,383.50. Following the purchase, the chief operating officer directly owned 18,319 shares in the company, valued at $1,268,224.37. This trade represents a 8.60% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Daniel G. Mcbride bought 3,000 shares of Cooper Companies stock in a transaction on Tuesday, September 2nd. The shares were bought at an average cost of $65.04 per share, with a total value of $195,120.00. Following the acquisition, the chief operating officer directly owned 63,120 shares in the company, valued at approximately $4,105,324.80. This represents a 4.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 17,975 shares of company stock worth $1,216,346 in the last three months. 1.98% of the stock is currently owned by corporate insiders.

Cooper Companies Stock Up 6.1%

COO opened at $75.47 on Friday. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $106.63. The company has a market cap of $15.00 billion, a PE ratio of 37.18, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. The company has a current ratio of 2.12, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The company has a 50 day moving average of $70.15 and a 200 day moving average of $71.98.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the business posted $0.96 earnings per share. The business’s quarterly revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies announced that its board has authorized a share buyback program on Wednesday, September 17th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Robert W. Baird reduced their price target on shares of Cooper Companies from $97.00 to $85.00 and set an “outperform” rating for the company in a research report on Thursday, August 28th. Barclays assumed coverage on shares of Cooper Companies in a research note on Monday, October 13th. They issued an “overweight” rating and a $85.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $94.00 target price on shares of Cooper Companies in a research report on Thursday, August 28th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Cooper Companies in a report on Wednesday. Finally, Morgan Stanley set a $76.00 price objective on Cooper Companies and gave the company an “equal weight” rating in a research note on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $84.77.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.